Opinion|Videos|October 9, 2024 (Updated: October 9, 2024)
Quantifying Success: Measuring Depth of Treatment Response in MDD
Experts in the management of mood disorders comment on how to assess and quantify treatment response in MDD, focusing on effective measurement strategies to guide clinical decisions
Advertisement
Episodes in this series
Advertisement
Related to this article
Medicare claims show pimavanserin in Parkinson psychosis nursing homes links to fewer falls and recurrent falls than quetiapine or other antipsychotics.
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
Advertisement
Advertisement
Trending on Psychiatric Times
1
New Adult ADHD Guidelines: What Resources Are Coming Soon
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
4
New Real-World Data Supporting Cariprazine for MDD and Bipolar I Depression
5